Free Trial

Schrödinger, Inc. (NASDAQ:SDGR) Receives $32.80 Average Price Target from Analysts

Schrödinger logo with Medical background

Schrödinger, Inc. (NASDAQ:SDGR - Get Free Report) has received an average recommendation of "Buy" from the six ratings firms that are covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company. The average 12-month price objective among brokers that have covered the stock in the last year is $32.80.

Several equities analysts have issued reports on the stock. KeyCorp upped their price target on shares of Schrödinger from $30.00 to $32.00 and gave the company an "overweight" rating in a research report on Wednesday, April 16th. Piper Sandler decreased their price objective on Schrödinger from $50.00 to $45.00 and set an "overweight" rating for the company in a report on Thursday, February 27th.

Read Our Latest Stock Report on Schrödinger

Insider Buying and Selling at Schrödinger

In other news, insider Karen Akinsanya sold 16,723 shares of the company's stock in a transaction on Monday, April 14th. The shares were sold at an average price of $25.09, for a total value of $419,580.07. Following the sale, the insider now directly owns 15,625 shares of the company's stock, valued at approximately $392,031.25. This represents a 51.70% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 8.60% of the company's stock.

Hedge Funds Weigh In On Schrödinger

Hedge funds and other institutional investors have recently bought and sold shares of the company. Point72 Hong Kong Ltd acquired a new stake in Schrödinger during the 4th quarter worth about $27,000. ANTIPODES PARTNERS Ltd bought a new stake in shares of Schrödinger during the 1st quarter valued at about $37,000. Paradigm Asset Management Co. LLC acquired a new stake in Schrödinger during the fourth quarter worth approximately $50,000. PNC Financial Services Group Inc. increased its holdings in Schrödinger by 29.9% in the first quarter. PNC Financial Services Group Inc. now owns 2,956 shares of the company's stock worth $58,000 after purchasing an additional 680 shares in the last quarter. Finally, KBC Group NV increased its holdings in Schrödinger by 73.9% in the fourth quarter. KBC Group NV now owns 4,361 shares of the company's stock worth $84,000 after purchasing an additional 1,853 shares in the last quarter. Institutional investors and hedge funds own 79.05% of the company's stock.

Schrödinger Price Performance

SDGR stock traded up $0.66 during midday trading on Tuesday, reaching $26.13. 1,686,462 shares of the stock were exchanged, compared to its average volume of 881,659. Schrödinger has a 52 week low of $16.60 and a 52 week high of $28.47. The company has a fifty day moving average price of $23.16 and a 200 day moving average price of $22.35. The stock has a market capitalization of $1.92 billion, a PE ratio of -11.17 and a beta of 1.63.

Schrödinger (NASDAQ:SDGR - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The company reported ($0.82) earnings per share for the quarter, missing the consensus estimate of ($0.81) by ($0.01). The firm had revenue of $59.55 million for the quarter, compared to the consensus estimate of $54.60 million. Schrödinger had a negative return on equity of 35.77% and a negative net margin of 91.84%. The business's revenue for the quarter was up 62.7% on a year-over-year basis. During the same quarter last year, the firm posted ($0.86) earnings per share. As a group, analysts anticipate that Schrödinger will post -2.37 earnings per share for the current fiscal year.

About Schrödinger

(Get Free Report

Schrödinger, Inc, together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries.

Featured Articles

Analyst Recommendations for Schrödinger (NASDAQ:SDGR)

Should You Invest $1,000 in Schrödinger Right Now?

Before you consider Schrödinger, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Schrödinger wasn't on the list.

While Schrödinger currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Analysts Are Watching These 4 Penny Stocks—You Should Too
Congress Is Pouring Millions Into These 6 Surprising Stocks
3 Dirt-Cheap Stocks in a Market That’s Getting Expensive

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines